Jing Luo, MD, MPH, is an Assistant Professor of Medicine and board-certified general internist. Before coming to Pitt, he was a member of the faculty at Harvard Medical School and a physician and researcher at the Division of Pharmacoepidemiology and Pharmacoeconomics, located within the Department of Medicine at the Brigham and Women’s Hospital. He trained in primary care internal medicine at Yale-New Haven Hospital.
His research focuses on prescription drug use, pricing, and policy, especially for medicines treating chronic diseases such as diabetes. His work on insulin has been featured in The Lancet, JAMA, the NYTimes, and the Washington Post.
He lives with his wife and 3 children in Squirrel Hill. He enjoys playing pickup basketball.
Education & Training
- BS (Biology), Duke University, 2006
- MD (Medicine), University of Illinois at Chicago College of Medicine, 2011
- Internship and Residency, Yale-New Haven Hospital, 2014
- MPH (Clinical Effectiveness), Harvard T.H. Chan School of Public Health, 2016
- Fellowship, General Internal Medicine and Primary Care Research, Brigham and Women’s Hospital, Harvard Medical School, 2016
Luo J, Khan NF, Manetti T, Rose J, Kaloghlian A, Gadhe B, Jain SH, Gagne JJ, Kesselheim AS. Implementation of a health plan program for switching from analogue to human insulin and glycemic control among Medicare beneficiaries with type 2 diabetes. JAMA. 2019;321(4): 374-384.
This study evaluated a health plan intervention switching older Medicare beneficiaries with type 2 diabetes from more costly, designer insulins to less expensive human insulins; showing that the intervention was not associated with a significant increase risk of hypoglycemia but resulted in a lower risk of reaching the Part D coverage gap (donut hole).
Luo J, Gonsalves G, Greene J. Insulin for all: treatment activism and the global diabetes crisis. Lancet (London, England). 2019;393(10186): 2116.
This perspective frames the fight to increase access to global insulin using the language, tactics and strategy of the treatment access movement people living with HIV/AIDS in the 1990s.
Luo J, Kesselheim AS, Avorn J. Medicaid expenditures and estimated rebates for epinephrine autoinjectors, 2012 to 2016. JAMA Internal Medicine. 2017 May 01; 177(5):734-736.
This research letter used estimates money Medicaid lost due to Mylan’s mis-classification of brand-name EpiPen as a generic product under the Medicaid Drug Rebate Program, finding that the proposed $465 million settlement underestimates the actual cost.
Luo J, Gagne JJ, Landon J, Avorn J, Kesselheim AS. Comparative effectiveness and safety of thalidomide and lenalidomide in patients with multiple myeloma in the United States of America: a population-based cohort study. European Journal of Cancer. 2017 Jan; 70:22-33.
This observational cohort study using commercial claims data from patients with multiple myeloma patients found that thalidomide and lenalidomide are equivalent with respect to survival outcomes but different with respect to neurotoxicity in real-world settings.
- Pharmaceutical policy and pricing
- Comparative effectiveness research
- Diabetes medications, insulin